Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 2Gynecologic 2Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 196Triple Negative Breast Neoplasms 26Neoplasm Metastasis 18Breast Neoplasms, Male 13Ovarian Neoplasms 9Inflammatory Breast Neoplasms 9Pancreatic Neoplasms 8Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Multiple Myeloma 2Lymphedema 2Hematologic Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

pembrolizumab 5spartalizumab 2durvalumab 2Immunohistochemistry 2Gemcitabine 2130-nm albumin-bound paclitaxel 2tremelimumab 1obinutuzumab 1naptumomab estafenatox 1liposomal doxorubicin 1elgemtumab 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1Mass Spectrometry 1Leucovorin 1LGK974 1Itraconazole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Fluorouracil 1EC regimen 1Cisplatin 1Carboplatin 1CP protocol 1Biopsy 1Bevacizumab 1Albumin-Bound Paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Bevacizumab × Breast × Clear all
NCT04925284 2025-04-04

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Exelixis

Phase 1 Completed
269 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡